Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Okyo Pharma Ltd (EMMLF)

Okyo Pharma Ltd (EMMLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Fri May 20, 2022

LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and...

OKYO : 1.1800 (-2.48%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing Globe Newswire - Thu May 19, 2022

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused...

OKYO : 1.1800 (-2.48%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Wed May 18, 2022

LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and...

OKYO : 1.1800 (-2.48%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation Globe Newswire - Tue May 17, 2022

LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing Globe Newswire - Mon May 16, 2022

LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Globe Newswire - Wed Apr 27, 2022

OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States Globe Newswire - Mon Mar 7, 2022

LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) ("OKYO" or the "Company"), a biotechnology company focused on...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain Globe Newswire - Wed Feb 23, 2022

LONDON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity Globe Newswire - Mon Feb 21, 2022

LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings Globe Newswire - Tue Feb 1, 2022

LONDON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)

Barchart Exclusives

Large Unusual Activity in Tesla Put Options Dominates the Options Market Today Barchart - 1 hour ago
Today there is large, unusual activity in Tesla options. This is almost certainly due to the recent rise in TSLA stock. The puts highlight investors' concerns about Tesla stock, but they also present good income plays. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot